| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 67184-0532-02 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 69097-0576-08 | 69097-0576 | nilotinib | NILCEYA | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 00069-8141-20 | 00069-8141 | Crizotinib | Xalkori | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Aug 26, 2011 | In Use | |
| 62332-0566-30 | 62332-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 51991-0376-90 | 51991-0376 | IMATINIB MESYLATE | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | Mar 31, 2023 | No Longer Used |
| 72606-0556-01 | 72606-0556 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 6, 2019 | In Use | |
| 57962-0560-28 | 57962-0560 | Ibrutinib | IMBRUVICA | 560.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb 16, 2018 | Feb 28, 2025 | In Use |
| 60505-2901-09 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
| 59923-0724-30 | 59923-0724 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 1, 2020 | In Use | |
| 59651-0464-28 | 59651-0464 | SUNITINIB MALATE | SUNITINIB MALATE | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Mar 14, 2024 | In Use | |
| 62332-0565-30 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 00078-0640-70 | 00078-0640 | Ceritinib | Zykadia | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Apr 29, 2014 | Feb 29, 2020 | In Use |
| 60505-3801-08 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
| 67184-0533-01 | 67184-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 72482-0100-12 | 72482-0100 | Pacritinib | Vonjo | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Oral | Feb 28, 2022 | In Use | |
| 47335-0472-13 | 47335-0472 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
| 00078-0649-30 | 00078-0649 | Imatinib Mesylate | Gleevec | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 23, 2014 | Dec 31, 2026 | In Use |
| 00093-8199-28 | 00093-8199 | Sunitinib Malate | Sunitinib Malate | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 22, 2021 | In Use | |
| 69189-0063-01 | 69189-0063 | Erlotinib Hydrochloride | Tarceva | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 1, 2015 | May 24, 2017 | No Longer Used |
| 68382-0914-06 | 68382-0914 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 16714-0677-01 | 16714-0677 | Sunitinib malate | Sunitinib malate | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Feb 18, 2022 | In Use | |
| 43598-0604-30 | 43598-0604 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 69189-0403-01 | 69189-0403 | Imatinib Mesylate | Gleevec | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 1, 2015 | May 24, 2017 | No Longer Used |
| 31722-0780-33 | 31722-0780 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 43598-0455-46 | 43598-0455 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use |
Found 12250 results — Export these results
Home